Antibody-mediated rejection after alemtuzumab induction: Incidence, risk factors, and predictors of poor outcome

Transplantation

Volumn 92, Issue 2, 2011, Pages 176-182

  Willicombe, Michelle ^a   Roufosse, Candice ^a   Brookes, Paul ^a   Galliford, Jack W ^a   McLean, Adam G ^a   Dorling, Anthony ^a   Warrens, Anthony N ^a   Cook, Terry H ^a   Cairns, Tom D ^a   Taube, David ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Alemtuzumab; Antibody mediated rejection; Donor specific antibodies

Indexed keywords

ALEMTUZUMAB; ANTIBODY; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; HLA ANTIGEN; HLA DR ANTIGEN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; COMPLEMENT C4B; FEMALE; GLYCOPROTEINS; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 79960325512     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318222c9c6     Document Type: Article

References (47)

1. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria\-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
2. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
3. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison ofmolecular- and histopathology-based ap-proaches. Am J Transplant 2009; 9: 1802.
4. Humar A, Kerr S, Gillingham KJ, et al. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200.
5. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7:832.
6. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes ofkidney allograft loss. Am J Transplant 2009; 9: 527.
7. Issa N, Cosio FG, Gloor JM, etal.Transplant glomerulopathy: Riskand prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
8. Sampaio MS, Kadiyala A, Gill J, et al. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation 2009; 88:904.
9. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing Registry Data. Transplantation 2010; 90: 1511.
10. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118.
11. Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement mediated lysis in the presence of alemtuzumab. Blood 2009; 114: 3052.
12. Bloom DD, Hu H, Fechner JH, et al. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81.
13. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
14. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative cam-path 1H, and low-dose cyclosporin monotherapy in renal allograft re-cipients. Lancet 1998; 351: 1701.
15. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
16. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
17. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009.
18. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008; 8: 1480.
19. Vathsala A, Ona ET, Tan SY, et al. Randomized trial ofalemtuzumab for prevention of graft rejection and preservation ofrenal function after kidneytransplantation. Transplantation 2005; 80: 765.
20. Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immuno-logical risk renal transplantation. Transplantation 2007; 83: 1509.
21. www.uktransplant.org.uk/ukt/about-transplant/organ-allocation. Accessed November 10, 2010.
22. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: Treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34.
23. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation\-Efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
24. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications ofdevelopment ofdonor-specific and non-donor-specific HLA antibodies after kidney transplantation. JAm Soc Nephrol 2005; 16: 2804.
25. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin JAm Soc Nephrol 2006; 1: 433.
26. Cai J, Terasaki PI, Bloom DD, et al. Correlation between human leu-kocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapyafter Campath-1H induction. Transplantation 2004; 78:919.
27. Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation 2008; 85: 1125.
28. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney trans-plant recipients does not predict acute rejection. Transplantation 2010; 89: 178.
29. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttrans-plant antidonor HLA antibodies is associated with acute humoral re-jection and earlygraft dysfunction. Transplantation 2005; 79: 591.
30. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962.
31. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am JTransplant 2009; 9: 1063.
32. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. JAm Soc Nephrol 2002; 13: 779.
33. Herzenberg AM, Gill JS, Djurdjev O, et al. C4d deposition in acute rejection: An independent long-term prognostic factor. JAm Soc Nephrol 2002; 13: 234.
34. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeu-tic implications. JAm Soc Nephrol 2002; 13: 242.
35. Magil AB, Tinckam KJ. Focal peritubular capillary C4d deposition in acuterejection. Nephrol Dial Transplant 2006; 21: 1382.
36. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
37. Rafiq MA, de Boccardo G, Schroppel B, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant 2009: 951.
38. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Sub-clinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124.
39. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant 2008; 8:492.
40. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
41. Rostaing L, Guilbeau-Frugier C, Fort M, et al. Treatment ofsymptom-atic transplant glomerulopathy with rituximab. Transpl Int 2009; 22: 906.
42. Worthington JE, Mc Ewen A, Mc William LJ, et al. Association between C4d staining in renal transplant biopsies, production ofdonor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398.
43. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (IV gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism ofaction. Transplantation 1998; 66: 800.
44. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6(5 Pt 1): 859.
45. Sun Q, Liu ZH, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 2007; 71: 24.
46. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
47. Locke JE, Magro CM, Singer AL, et al. The use ofantibody to comple-ment protein C5 for salvage treatment of severe antibody-mediated rejection.Am JTransplant 2009; 9:231.